Unit 1 SIGS Flashcards
What are the CFTR gene mutation classes?
Class I - no protein - channel not made at all
Class II - no transport - channel not transported to cell membrane
Class III - no function - channel on cell membrane but doesn’t work
Class IV - less function - channels work but poor/decreased function
Class V - less protein - not enough channels made
Class VI - not stable - channels work but aren’t stable, need frequent replacement
Describe the Class I CFTR gene mutation pathophysiology
The result of a nonsense, frameshift or splice-site mutation leads to premature termination of the mRNA sequence –> no protein made –> absence of Cl- channel
Describe the Class II CFTR gene mutation pathophysiology
Abnormal post-translational processing of the CFTR protein –> channel unable to move to proper location
Describe the Class III CFTR gene mutation pathophysiology
Diminished protein activity in response to intracellular signaling –> fully formed channel but non-functioning
Describe the Class IV CFTR gene mutation pathophysiology
CFTR protein has been produced and correctly localized to the cell surface, but rate of chloride ion flow and duration of channel activation after stimulation is decreased from normal
Describe the Class V CFTR gene mutation pathophysiology
Decreased concentration of CFTR channels in the cell membrane as a result of rapid degradation.
Describe the Class VI CFTR gene mutation pathophysiology
Channel instability leads to rapid turnover and decreased net function
Describe the pathway of glycogenesis
Glucose –> (Glucokinase) –> G6P –> Glucose-1-Phosphate –> UDP-Glucose –> linear glycogen –> (branching enzyme) –> branched glycogen –> (Glycogen phosphorylase) –> Limit Dextrin –> (4-a-D-glucanotransferase) –> Modified Limit Dextrin –> (a-1,6-glucosidase) –> Glycogen
Discuss the function of Glucose-6-Phosphatase
Converts Glucose-6-Phosphate into glucose
What is the inheritance pattern of glycogen storage disease?
Autosomal recessive
Describe the importance of dietary therapy in the management of von Gierke disease
Foods rich in fructose or galactose need to be avoided - they need to be converted to G6P before they can be utilized
Cornstarch helps prevent hypoglycemic events
Outline the pathophys and clinical presentation of Type I GSD
Von Gierke Disease - mutation on G6PC gene for G6Pase - diminished G6Pase can’t convert Glucose-6-Phospohate into glucose
Clinical presentation:
Hepatomegaly, renomegaly from increased glycogen and lipids
Hypoglycemic tremor, confusion, seizures
Gout
“Doll-like” faces
Outline the pathophys and clinical presentation of Type II GSD
Pompe disease - impaired glycogenolysis - defective Lysosomal acid a-1,4 glucosidase –> decrease of branch hydrolysis –> increase glycogen in cardiac muscle - affects tissue
Clinical presentation
Progressive
Failure to thrive, proximal myopathy, exercise intolerance
Hypertrophic cardiomyopathy
Respiratory failure
Early death
Outline the pathophys and clinical presentation of Type III GSD
Cori’s disease - impaired glycogenolysis, functional gluconeogenesis
Defective AGL gene –> decrease in debranching enzymes –> increase limit dextrin
Clinical presentation:
Failure to thrive, muscle weakness, cramps
Hepatomegaly, possible cirrhosis or cardiomyopathy
Needs high protein diet with cornstarch supplementation
Outline the pathophys and clinical presentation of Type IV GSD
Anderson disease - impaired glycogenesis - defective GBE1 gene –> branching enzyme depletion –> decreased branched glycogen - affects tissue and liver
Clinical presentation:
Failure to thrive
Hepatosplenomegaly
Hypotonia, cardiomyopathy
Peripheral neuropath
Early death
Outline the pathophys and clinical presentation of Type V GSD
McArdle disease - impaired glycogenolysis - defective PYGM gene –> decreased muscle phosphorylase
Clinical presentation
Older child/adolescent
Muscle weakness, cramps, exercise intolerance
Rhabdomyolysis, myoglobinuria
Outline the pathophys and clinical presentation of Type VI GSD
Hers disease - Impaired glycogenolysis - defective PYGL gene - decreased hepatic phosphorylase –> no debranching of glycogen
Presentation:
Hepatomegaly, hepatic fibrosis
Poor metabolic control –> short stature, delayed puberty, osteopenia, osteoporosis
How does Type I GSD affect serum levels of glucose, lactate, uric acid, and lipids?
Decreased plasma glucose levels
Elevated lactic acid levels
Elevated triglyceride levels
Elevated uric acid levels
Clinical presentation of Barrett’s Esophagus
Retrosternal burning
Regurgitation with water brash
Worse when supine and after eating
How does smoking increase the risk of Barrett’s Esophagus?
Nicotine relaces smooth muscle –> relaxing the lower esophageal sphincter allows gastric juices to get through
Reduced amount of HCO3 in saliva –> decreased acid neutralizing compound
Induces inflammation –> decrease peristalsis –> disrupts clearance of stomach acid from esophagus
When does GERD turn into Barret Esophagus?
When there is metaplasia of the distal esophageal –> change from squamous to columnar
Explain the pathophysiology of treatment options for Barret esophagus
Antacids - increase pH of stomach acid (neutralize)
Histamine blockers - prevents increase of gastric acid after meals
Proton pump inhibitors - decrease amount of H+ ions pumped into stomach
Inheritance pattern of Sickle Cell Disease
autosomal recessive
Explain the pathogenesis of Sickle Cell Disease
Sickle cell disease - ɑɑSS (homozygous)
Hemoglobin SC disease - ɑɑSC (double mutation)
Sickle cell trait - ɑɑβS (heterozygous)
Globin S chain –> B missense mutation on C11 (Glu(-) –> Val(0))
Globin C chain –> B missense mutation on C11 (Glu(-) –> Lys(+))
Describe the Sickle Cell Disease pathophysiology
In the deoxygenated form of HbS, the valine becomes buried in a hydrophobic pocket on an adjacent beta-globin chain. This joines the molecules together to form insoluble polymers. When enough of these form, it gives rise to the classic sickled shape
Outline the clinical presentation of Sickle Cell disease
General anemia features
Vaso-occlusive events - hallmark
Asplenia
Hematuria
Recurring infections (due to loss of splenic function)
Most distinguishing clinical feature of Sickle Cell Disease
Acute vaso-occlusion pain
Sickle cells lack elasticity –> adhere to endothelium –> causes vasoocclusion –> stroke, acute chest syndrome (pulmonary hypertension), splenic sequestration
How does Sickle Cell Disease affect vital signs?
Lower blood pressure than normal reference ranges
Higher blood pressures are at risk for stroke
Diagnostic tests of Sickle Cell Anemia
Hemoglobin electrophoresis - checking for fetal hgb
PBS
Justify the use of hydroxyurea therapy for Sickle Cell Disease
Hydroxyurea therapy uses an antineoplastic drug to inhibit ribonucleotide reductase
This inhibits DNA replication and causes cell cycle arrest in S phase
Increased nitric oxide levels and cGMP signaling lead to an increase in HgbF